Arginase Activity - A Marker of Disease Status in Patients with Visceral Leishmaniasis in Ethiopia

PLoS Neglected Tropical Diseases

Volumn 7, Issue 3, 2013, Pages

  Abebe, Tamrat ^a,b   Takele, Yegnasew ^c   Weldegebreal, Teklu ^c   Cloke, Tom ^d   Closs, Ellen ^e   Corset, Camille ^d   Hailu, Asrat ^a   Hailu, Workagegnehu ^c   Sisay, Yifru ^c   Corware, Karina ^d   Corset, Margaux ^f   Modolell, Manuel ^g   Munder, Markus ^e   Tacchini Cottier, Fabienne ^b   Müller, Ingrid ^d   Kropf, Pascale ^f  

^a ADDIS ABABA UNIVERSITY   (Ethiopia)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSITY OF GONDAR   (Ethiopia)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^g MAX PLANCK INSTITUTE OF IMMUNOBIOLOGY AND EPIGENETICS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE; ARGININE; CD15 ANTIGEN; CD3 ANTIGEN;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DEGRANULATION; ENZYME ACTIVITY; ENZYME METABOLISM; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MACROPHAGE; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; VISCERAL LEISHMANIASIS;

EID: 84875982208     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002134     Document Type: Article

References (46)

1. WHO (2010) Control of the Leishmaniases. Available: http://whqlibdoc.who.int/trs/WHO_TRS_949_eng.pdf. Accessed 19 February 2013.
2. (2006) Visceral leishmaniasis diagnosis & treatment guideline for health workers in Ethiopia. Ministry of Health E. 1st Edition ed.
3. Mengistu G, Ayele B, (2007) Visceral leishmaniasis and HIV co-infection in patients admitted to Gondar University Hospital, northwest Ethiopia. Ethiop J Health Dev 21: 53-60.
4. Kaye P, Scott P, (2011) Leishmaniasis: complexity at the host-pathogen interface. Nat Rev Microbiol 9: 604-615.
5. Cenini P, Berhe N, Hailu A, McGinnes K, Frommel D, (1993) Mononuclear cell subpopulations and cytokine levels in human visceral leishmaniasis before and after chemotherapy. J Infect Dis 168: 986-993.
6. Hailu A, van Baarle D, Knol GJ, Berhe N, Miedema F, et al. (2005) T cell subset and cytokine profiles in human visceral leishmaniasis during active and asymptomatic or sub-clinical infection with Leishmania donovani. Clin Immunol 117: 182-191.
7. Kurkjian KM, Mahmutovic AJ, Kellar KL, Haque R, Bern C, et al. (2006) Multiplex analysis of circulating cytokines in the sera of patients with different clinical forms of visceral leishmaniasis. Cytometry A 69: 353-358.
8. Nylen S, Maurya R, Eidsmo L, Manandhar KD, Sundar S, et al. (2007) Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis. J Exp Med 204: 805-817.
9. Sundar S, Reed SG, Sharma S, Mehrotra A, Murray HW, (1997) Circulating T helper 1 (Th1) cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. Am J Trop Med Hyg 56: 522-525.
10. Thakur CP, Mitra DK, Narayan S, (2003) Skewing of cytokine profiles towards T helper cell type 2 response in visceral leishmaniasis patients unresponsive to sodium antimony gluconate. Trans R Soc Trop Med Hyg 97: 409-412.
11. Cillari E, Vitale G, Arcoleo F, D'Agostino P, Mocciaro C, et al. (1995) In vivo and in vitro cytokine profiles and mononuclear cell subsets in Sicilian patients with active visceral leishmaniasis. Cytokine 7: 740-745.
12. Nylen S, Sacks D, (2007) Interleukin-10 and the pathogenesis of human visceral leishmaniasis. Trends Immunol 28: 378-384.
13. Goto H, Prianti MG, (2009) Immunoactivation and immunopathogeny during active visceral leishmaniasis. Rev Inst Med Trop Sao Paulo 51: 241-246.
14. Bronte V, Zanovello P, (2005) Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 5: 641-654.
15. Rodriguez PC, Ochoa AC, (2008) Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev 222: 180-191.
16. Munder M, (2009) Arginase: an emerging key player in the mammalian immune system. Br J Pharmacol 158: 638-651.
17. Modolell M, Choi B-S, Ryan RO, Hancock M, Titus RG, et al. (2009) Local suppression of T cell responses by arginase-induced L-arginine depletion in nonhealing leishmaniasis. PLoS Neglected Tropical Diseases 14: e480.
18. Osorio EY, Zhao W, Espitia C, Saldarriaga O, Hawel L, et al. (2012) Progressive visceral leishmaniasis is driven by dominant parasite-induced STAT6 activation and STAT6-dependent host arginase 1 expression. PLoS Pathog 8: e1002417.
19. Kropf P, Baud D, Marshall SE, Munder M, Mosley A, et al. (2007) Arginase activity mediates reversible T cell hyporesponsiveness in human pregnancy. Eur J Immunol 37: 935-945.
20. Closs EI, Ostad MA, Simon A, Warnholtz A, Jabs A, et al. (2012) Impairment of the extrusion transporter for asymmetric dimethyl-l-arginine: A novel mechanism underlying vasospastic angina. Biochem Biophys Res Commun 423: 218-223.
21. Cloke T, Garvery L, Choi BS, Abebe T, Hailu A, et al. (2010) Increased arginase activity correlates with disease severity in HIV seropositive patients. Journal of Infectious Diseases 202: 374-385.
22. WHO (1999) Management of severe malnutrition: a manual for physicians and other senior health workers. Available: http://www.who.int/nutrition/publications/severemalnutrition/en/manage_severe_malnutrition_eng.pdf. Accessed 19 February 2013.
23. Munder M, Mollinedo F, Calafat J, Canchado J, Gil-Lamaignere C, et al. (2005) Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity. Blood 105: 2549-2556.
24. Kuijpers TW, Tool AT, van der Schoot CE, Ginsel LA, Onderwater JJ, et al. (1991) Membrane surface antigen expression on neutrophils: a reappraisal of the use of surface markers for neutrophil activation. Blood 78: 1105-1111.
25. Schmielau J, Finn OJ, (2001) Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res 61: 4756-4760.
26. Denny MF, Yalavarthi S, Zhao W, Thacker SG, Anderson M, et al. (2010) A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. J Immunol 184: 3284-3297.
27. Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, et al. (2009) Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 69: 1553-1560.
28. Martin-Martin B, Nabokina SM, Blasi J, Lazo PA, Mollinedo F, (2000) Involvement of SNAP-23 and syntaxin 6 in human neutrophil exocytosis. Blood 96: 2574-2583.
29. Rotondo R, Bertolotto M, Barisione G, Astigiano S, Mandruzzato S, et al. (2011) Exocytosis of azurophil and arginase 1-containing granules by activated polymorphonuclear neutrophils is required to inhibit T lymphocyte proliferation. J Leukoc Biol 89: 721-727.
30. Cloke T, Munder M, Taylor GP, Müller I, Kropf P, (2012) Characterization of a novel population of low-density granulocytes associated with disease severity in HIV seropositive patients. PLOS ONE In press.
31. Mukhopadhyay D, Das NK, Roy S, Kundu S, Barbhuiya JN, et al. (2011) Miltefosine effectively modulates the cytokine milieu in Indian post kala-azar dermal leishmaniasis. J Infect Dis 204: 1427-1436.
32. Zea AH, Culotta KS, Ali J, Mason C, Park HJ, et al. (2006) Decreased Expression of CD3 zeta and Nuclear Transcription Factor kappa B in Patients with Pulmonary Tuberculosis: Potential Mechanisms and Reversibility with Treatment. J Infect Dis 194: 1385-1393.
33. Padilla H, Sanchez A, Powell RN, Umezawa C, Swendseid ME, et al. (1971) Plasma amino acids in children from Guadalajara with kwashiorkor. Am J Clin Nutr 24: 353-357.
34. Poeze M, Bruins MJ, Luiking YC, Deutz NE, (2010) Reduced caloric intake during endotoxemia reduces arginine availability and metabolism. Am J Clin Nutr 91: 992-1001.
35. Moyano D, Vilaseca MA, Artuch R, Lambruschini N, (1998) Plasma amino acids in anorexia nervosa. Eur J Clin Nutr 52: 684-689.
36. Youn JI, Gabrilovich DI, (2010) The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol 40: 2969-2975.
37. Abebe T, Hailu A, Woldeyes M, Mekonene W, Bilch K, et al. (2012) Local increase of arginase activity in lesions of patients with cutaneous leishmaniasis in Ethiopia. PLoS NTD 6: e1684.
38. Gidwani K, Jones S, Kumar R, Boelaert M, Sundar S, Interferon-gamma release assay (modified QuantiFERON) as a potential marker of infection for Leishmania donovani, a proof of concept study. PLoS Negl Trop Dis 5: e1042.
39. Ansari NA, Kumar R, Gautam S, Nylen S, Singh OP, et al. (2011) IL-27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis. J Immunol 186: 3977-3985.
40. Cloke T (2011) Immunoregulation by arginase mediated L-arginine metabolism in HIV seropostive patients. London: Imperial College London.
41. Kotsakis A, Harasymczuk M, Schilling B, Georgoulias V, Argiris A, et al. (2012) Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. J Immunol Methods 381: 14-22.
42. Haverkamp JM, Crist SA, Elzey BD, Cimen C, Ratliff TL, (2011) In vivo suppressive function of myeloid-derived suppressor cells is limited to the inflammatory site. Eur J Immunol 41: 749-759.
43. da Silva ER, Castilho TM, Pioker F, Tomich de Paula Silva CH, Floeter-Winter LM, (2002) Genomic organisation and transcription characterisation of the gene encoding Leishmania (L.) amazonensis arginase and its protein structure prediction. Int J Parasitol 32: 727-737.
44. Kropf P, Herath S, Weber V, Modolell M, Müller I, (2003) Factors influencing Leishmania major infection in IL-4 deficient BALB/c mice. Parasite Immunol 25: 439-447.
45. Gaur U, Roberts SC, Dalvi RP, Corraliza I, Ullman B, et al. (2007) An effect of parasite-encoded arginase on the outcome of murine cutaneous leishmaniasis. J Immunol 179: 8446-8453.
46. Singh S, (2006) New developments in diagnosis of leishmaniasis. Indian J Med Res 123: 311-330.